ClinicalTrials.gg
CompletedNCT01020838Updated Nov 10, 2026Results posted

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

A Phase 3 interventional study of Florbetaben (BAY94-9172) in Alzheimer Disease, sponsored by Lantheus Biosciences Ltd.. Completed at 19 sites in 5 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Lantheus Biosciences Ltd. (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic

Updated Nov 10, 2026Posted results revisedSponsor changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
397th of 1,611
218 · median 73
Started
2009
with 87 others
Phase 3
188 of 1,942
19 open now
Registered
381st of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 397th largest by enrollment of the 1,611 interventional ones that give a count, is one of 88 that started in 2009, is one of 188 in phase 3, and was the 381st registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective histopathologic post mortem specimens as the standard of truth

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Florbetaben
  • Amyloid beta-protein
  • Alzheimer's disease
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females, no or negative urine pregnancy test on day of BAY94-9172 injection
  • Exhibits visual, auditory, and communicative capabilities adequate to provide or assent and comply with study procedures
  • Is willing and able to lie down in magnetic resonance imaging (MRI) and positron emission tomography (PET) scanners
  • Is willing to donate their brain for postmortem examination in case of death
  • The subject, or the subject and/or legally acceptable representative will be compliant and have a high probability of completing the study in the opinion of the investigator
  • Has been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA), as applicable, and informed consent or assent has been signed and dated (with time) by the subject and/or the subject's legally acceptable representative
  • The subjects who have participated in a previous florbetaben study e.g. study 311741 may be included in the present study. The MRI- and florbetaben PET scan do not need to be repeated if both scans were performed within twelve months prior to inclusion.

Exclusion criteria

Exclusion Criteria:

  • Has severe cerebral macrovascular (ie, multi-stroke) disease or brain tumor (/brain cancer) as verified by MRI
  • Has any to magnetic resonance imaging (MRI) examination, eg, metal implants or phobia as determined by the onsite radiologist performing the scan
  • Has been previously enrolled in this study or participated in a clinical study involving an pharmaceutical product within 30 days prior to screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
  • Has severe cardio-vascular instability requiring intensive care surveillance and/or therapeutic intervention (i.e. catecholamine infusion)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Florbetaben (BAY94-9172)

    Drug: Florbetaben (BAY94-9172)

Interventions

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens

    The sensitivity/specificity of the visual assessment were calculated based on the majority read assessment of regional tracer uptake. This result was derived from assessments by 3 independent readers for brain regions of a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was a centralized histopathological determination of β-amyloid presence/absence based on both Bielschowsky silver and immunohistochemical staining. Based on the PET images, a brain region was classified as "normal" or "abnormal" depending on the presence or absence of regional tracer uptake in the respective region. "Normal" therefore meant absence of β-amyloid and "abnormal" presence of β-amyloid. Sensitivity was defined as the percentage of abnormal brain regions from all regions where an SOT was available and the SOT was "β-amyloid present". Specificity was defined as the percentage of normal brain regions from all regions where an SOT was available and was "β-amyloid not present".

    Time frame: 90-110 minutes post injection (PET image acquisition)

Secondary outcomes

  1. Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification With Bielschowsky Silver Staining (SOT 1).

    Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining (SOT 1). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".

    Time frame: 90-110 minutes post injection (PET image acquisition)

  2. Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With Histopathological Verification With Bielschowsky Silver Staining and Immunohistochemistry (SOT 2).

    Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining and immunohistochemistry (SOT 2). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".

    Time frame: 90-110 minutes post injection (PET image acquisition)

  3. Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification According to CERAD Criteria (SOT 3).

    Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a histopathological assessment of the presence/absence of β-amyloid according to CERAD Criteria (SOT 3). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".

    Time frame: 90-110 minutes post injection (PET image acquisition)

  4. Sensitivity and Specificity of the Subject Level Composite SUVR Calculated Based on Pathology Results.

    Sensitivity and specificity of subject level composite Standard Uptake Value Ratios (SUVR) by SOT for subjects with available brain tissue and 10 healthy volunteers. The SUVR were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of the tissue radioactivity concentration c (in MBq/kg) at time point t, and the injected activity (in MBq), extrapolated to the same time (t) divided by the body weight (in kg). SUV numbers were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference. SOTs comprised Bielschowsky silver staining (SOT 1), Bielschowsky silver staining with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans. The optimal threshold for the distinction between β-amyloid present yes/no according to the respective SOT was derived based on ROC curve analyses and used to calculate sensitivity and specificity.

    Time frame: 90-110 minutes post injection (PET image acquisition)

  5. Subject Level Composite SUVRs by SOT for Baseline and Available Follow-Up Scans

    Subject level composite SUVRs (calculated as mean of SUVRs from the frontal, parietal, lateral temporal, anterior and posterior cingulate, and occipital cortices) by SOT are reported for subjects with available brain tissue. The initial drug administration group includes additionally 10 healthy controls who were considered as ß-amyloid negative. The SOTs for deceased subjects were based on Bielschowsky silver staining (SOT 1), Bielschowsky silver staining in combination with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans.

    Time frame: 90-110 minutes post injection (PET image acquisition)

07

Results

Posted Mar 25, 2015

Participant flow

Subjects were screened at 15 study centers in Australia, Germany, France, Japan, and the U.S.

Participant flow — Overall Study
MilestoneAll Study Participants
Started218
Safety analysis set216
Interim analysis set (primary efficacy)41
Final analysis set (whole brain)97
First annual repeat injection91
Second annual repeat injection34
Completed35
Not completed183
Withdrew: Death90
Withdrew: Adverse event1
Withdrew: Withdrawal by subject9
Withdrew: Lost to follow-up6
Withdrew: Most common: study ended by sponsor77

Outcome measures

PrimarySensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens

The sensitivity/specificity of the visual assessment were calculated based on the majority read assessment of regional tracer uptake. This result was derived from assessments by 3 independent readers for brain regions of a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was a centralized histopathological determination of β-amyloid presence/absence based on both Bielschowsky silver and immunohistochemical staining. Based on the PET images, a brain region was classified as "normal" or "abnormal" depending on the presence or absence of regional tracer uptake in the respective region. "Normal" therefore meant absence of β-amyloid and "abnormal" presence of β-amyloid. Sensitivity was defined as the percentage of abnormal brain regions from all regions where an SOT was available and the SOT was "β-amyloid present". Specificity was defined as the percentage of normal brain regions from all regions where an SOT was available and was "β-amyloid not present".

Time frame:
90-110 minutes post injection (PET image acquisition)
Reported as:
Number · percentage of regions
Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens
percentage of regionsSensitivity (Interim Analysis Set)Specificity (Interim Analysis Set)
Total77.3694.20
Frontal Cortex85.7195.00
Occipital Cortex88.8986.36
Hippocampus57.14100.00
Anterior Cingulate Cortex90.0085.71
Posterior Cingulate Cortex81.8294.44
Cerebellar Cortex0.00100.00
Statistical analysis
  • Sensitivity (Interim Analysis Set) · Sensitivity: 0.774 · 95% CI 0.654 to 0.894Point estimate of sensitivity was calculated by the method of Rao and Scott. Variance for sensitivity is based on subjects that contribute at least one brain region, which is amyloid positive according to the SoT
  • Specificity (Interim Analysis Set) · Specificity: 0.942 · 95% CI 0.886 to 0.998Point estimate of specificity was calculated using the method of Rao and Scott. Variance for specificity is based on subjects that contribute at least one brain region, which is amyloid negative according to the SoT
SecondarySensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification With Bielschowsky Silver Staining (SOT 1).

Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining (SOT 1). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".

Time frame:
90-110 minutes post injection (PET image acquisition)
Reported as:
Number · percentage of subjects
Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification With Bielschowsky Silver Staining (SOT 1).
percentage of subjectsFull Analysis Set Final Clinical Study Report
Sensitivity96.49 (91.71 to 100.00)
Specificity85.00 (73.93 to 96.07)
SecondarySensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With Histopathological Verification With Bielschowsky Silver Staining and Immunohistochemistry (SOT 2).

Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining and immunohistochemistry (SOT 2). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".

Time frame:
90-110 minutes post injection (PET image acquisition)
Reported as:
Number · percentage of subjects
Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With Histopathological Verification With Bielschowsky Silver Staining and Immunohistochemistry (SOT 2).
percentage of subjectsFull Analysis Set Final Clinical Study Report
Sensitivity96.72 (92.25 to 100.00)
Specificity94.44 (86.96 to 100.00)
SecondarySensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification According to CERAD Criteria (SOT 3).

Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a histopathological assessment of the presence/absence of β-amyloid according to CERAD Criteria (SOT 3). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".

Time frame:
90-110 minutes post injection (PET image acquisition)
Reported as:
Number · percentage of subjects
Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification According to CERAD Criteria (SOT 3).
percentage of subjectsFull Analysis Set Final Clinical Study Report
Sensitivity96.49 (91.71 to 100.00)
Specificity85.00 (73.93 to 96.07)
SecondarySensitivity and Specificity of the Subject Level Composite SUVR Calculated Based on Pathology Results.

Sensitivity and specificity of subject level composite Standard Uptake Value Ratios (SUVR) by SOT for subjects with available brain tissue and 10 healthy volunteers. The SUVR were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of the tissue radioactivity concentration c (in MBq/kg) at time point t, and the injected activity (in MBq), extrapolated to the same time (t) divided by the body weight (in kg). SUV numbers were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference. SOTs comprised Bielschowsky silver staining (SOT 1), Bielschowsky silver staining with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans. The optimal threshold for the distinction between β-amyloid present yes/no according to the respective SOT was derived based on ROC curve analyses and used to calculate sensitivity and specificity.

Time frame:
90-110 minutes post injection (PET image acquisition)
Reported as:
Number · percentage of subjects
Sensitivity and Specificity of the Subject Level Composite SUVR Calculated Based on Pathology Results.
percentage of subjectsSensitivity of Subject Level Composite SUVR by SOTSpecificity of Subject Level Composite SUVR by SOT
SOT 1 (initial period)8982
SOT 2 (initial period)9091
SOT 3 (initial period)8990
SOT 1 (last available scan)8885
SOT 2 (last available scan)8994
SOT 3 (last available scan)9587
SecondarySubject Level Composite SUVRs by SOT for Baseline and Available Follow-Up Scans

Subject level composite SUVRs (calculated as mean of SUVRs from the frontal, parietal, lateral temporal, anterior and posterior cingulate, and occipital cortices) by SOT are reported for subjects with available brain tissue. The initial drug administration group includes additionally 10 healthy controls who were considered as ß-amyloid negative. The SOTs for deceased subjects were based on Bielschowsky silver staining (SOT 1), Bielschowsky silver staining in combination with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans.

Time frame:
90-110 minutes post injection (PET image acquisition)
Reported as:
Mean · Standardized Uptake Value Ratio (SUVR)
Subject Level Composite SUVRs by SOT for Baseline and Available Follow-Up Scans
Standardized Uptake Value Ratio (SUVR)Initial Drug Administration1st Repeat Drug Administration2nd Repeat Drug Administration
SOT 1 (abeta absent)1.296 ± 0.2321.319 ± 0.4141.537 ± NA
SOT 1 (abeta present)1.707 ± 0.2761.625 ± 0.2501.699 ± 0.046
SOT 2 (abeta absent)1.237 ± 0.1401.175 ± 0.3641.537 ± NA
SOT 2 (abeta present)1.714 ± 0.2731.632 ± 0.2441.699 ± 0.046
SOT 3 (abeta absent)1.263 ± 0.1701.260 ± 0.390NA ± NA
SOT 3 (abeta present)1.729 ± 0.2701.639 ± 0.2361.645 ± 0.099

Adverse events

Collected over All treatment emergent adverse events were recorded within 7 days of the application or follow-up application of study drug.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Drug Administration—12/216 (5.6%)48/216 (22.2%)
1st Repeat Drug Administration—0/91 (0%)22/91 (24.2%)
2nd Repeat Drug Administration—0/34 (0%)14/34 (41.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventInitial Drug Administration1st Repeat Drug Administration2nd Repeat Drug Administration
Frontotemporal dementiaNervous system disorders1/2160/910/34
Dementia, Alzheimers' typeNervous system disorders1/2160/910/34
ColitisGastrointestinal disorders1/2160/910/34
PneumoniaInfections and infestations1/2160/910/34
Spinal compression fractureMusculoskeletal and connective tissue disorders1/2160/910/34
Pneumonia aspirationInfections and infestations1/2160/910/34
Pubis fractureInjury, poisoning and procedural complications1/2160/910/34
ArthralgiaMusculoskeletal and connective tissue disorders1/2160/910/34
Colon cancerGastrointestinal disorders1/2160/910/34
Hepatic cancer metastaticHepatobiliary disorders1/2160/910/34
Most frequent other events
Showing 10 of 23
Most frequent other events
EventInitial Drug Administration1st Repeat Drug Administration2nd Repeat Drug Administration
HaematomaVascular disorders1/2165/916/34
ErythemaSkin and subcutaneous tissue disorders1/2164/913/34
Injection site hemorrhageGeneral disorders1/2164/912/34
Injection site hematomaGeneral disorders10/2161/910/34
Puncture site reactionGeneral disorders7/2164/910/34
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders1/2163/911/34
PyrexiaGeneral disorders7/2162/910/34
Injection site erythemaGeneral disorders4/2160/911/34
HypertensionVascular disorders5/2161/911/34
AsthmaRespiratory, thoracic and mediastinal disorders0/2160/911/34

Baseline characteristics

Participants in the safety analysis set were treated with study drug.

Age, Continuous
Age, Continuous(years)Safety Analysis Set
Mean74.4 ± 15.4
Sex: Female, Male
Sex: Female, Male(Participants)Safety Analysis Set
Female104
Male112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Safety Analysis Set
Hispanic or Latino3
Not Hispanic or Latino213
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Analysis Set
American Indian or Alaska Native0
Asian55
Native Hawaiian or Other Pacific Islander0
Black or African American2
White159
More than one race0
Unknown or Not Reported0
BMI (kg/m^2)
BMI (kg/m^2)(kg/m^2)Safety Analysis Set
Mean23.617 ± 5.213
Body weight
Body weight(kg)Safety Analysis Set
Mean64.95 ± 18.44
Height
Height(cm)Safety Analysis Set
Mean164.70 ± 12.34
Baseline clinical diagnosis
Baseline clinical diagnosis(participants)Safety Analysis Set
Alzheimer's Disease137
Dementia with Lewy bodies5
Other dementia subject31
Healthy volunteers32
Healthy negative control11
08

Study locations

19 sites
  • Sun City, Arizona 85351, United States
  • Stanford, California 94305, United States
  • Tampa, Florida 33616, United States
  • Teaneck, New Jersey 07666, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Dallas, Texas 75390, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78229, United States
  • Heidelberg, Victoria 3084, Australia
  • Lille, 59037, France
  • Strasbourg, 67091, France
  • Jülich, North Rhine-Westphalia 52425, Germany
  • Leipzig, Saxony 04103, Germany
  • Toyohashi, Aichi-ken 440-0045, Japan
  • Toyohashi, Aichi-ken 441-8021, Japan
  • Toyohashi, Aichi-ken 441-8124, Japan
  • Isesaki, Gunma 372-0006, Japan
  • Hamamatsu, Shizuoka 432-8580, Japan
  • tabashi City, Tokyo 173-0015, Japan
09

References and documents

Publications

  • Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Takao M, Akatsu H, Murayama S, Bullich S, Mueller A, Koglin N, Schulz-Schaeffer WJ, Hoffmann A, Sabbagh MN, Stephens AW, Sabri O. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study. J Nucl Med. 2016 Jun;57(6):900-6. doi: 10.2967/jnumed.115.161927. Epub 2016 Jan 28. PubMed 26823561 ↗
  • Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015 Aug;11(8):964-74. doi: 10.1016/j.jalz.2015.02.004. Epub 2015 Mar 28. PubMed 25824567 ↗
10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Sep 2011 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 3 years 6 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2009
First posted
Nov 26, 2009
Start
Nov 2009
Primary completionActual
Sep 2011
CompletionActual
Dec 2013
Results delay requested
May 9, 2013
Results first posted
Mar 25, 2015
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 10, 2026
Sites
7 sites added, 7 sites removed
Show 7 added (5 Japan, 2 Germany)
  • Jülich · Jülich, Germany
  • Leipzig · Leipzig, Germany
  • Toyohashi · Toyohashi, Japan
  • Toyohashi · Toyohashi, Japan
  • Toyohashi · Toyohashi, Japan
  • Isesaki · Isesaki, Japan
  • tabashi City · tabashi City, Japan
Show 7 removed
  • Jülich · Jülich, Germany
  • Leipzig · Leipzig, Germany
  • Toyohashi · Toyohashi, Japan
  • Toyohashi · Toyohashi, Japan
  • Toyohashi · Toyohashi, Japan
  • Isezaki · Isezaki, Japan
  • Itabashi-ku · Itabashi-ku, Japan
Nov 10, 2026
Sponsor
Life Molecular Imaging SA→Lantheus Biosciences Ltd.
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Posted results revised
    7 sites added, 7 sites removed
    Show 7 added (5 Japan, 2 Germany)
    • Jülich · Jülich, Germany
    • Leipzig · Leipzig, Germany
    • Toyohashi · Toyohashi, Japan
    • Toyohashi · Toyohashi, Japan
    • Toyohashi · Toyohashi, Japan
    • Isesaki · Isesaki, Japan
    • tabashi City · tabashi City, Japan
    Show 7 removed
    • Jülich · Jülich, Germany
    • Leipzig · Leipzig, Germany
    • Toyohashi · Toyohashi, Japan
    • Toyohashi · Toyohashi, Japan
    • Toyohashi · Toyohashi, Japan
    • Isezaki · Isezaki, Japan
    • Itabashi-ku · Itabashi-ku, Japan
    Sponsor Life Molecular Imaging SA→Lantheus Biosciences Ltd.
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01020838
Responsible party
Sponsor
First posted
Nov 26, 2009
Start date
Nov 2009
Primary completion
Sep 2011
Completion
Dec 2013
Results posted
Mar 25, 2015
Last update
Nov 10, 2026

Study contacts

Andrew Stephens, MD, PhD
study director · Lantheus Germany GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florbetaben f-18

Start the discussion